埃達珠單抗
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | 整合素αVβ3 |
| 臨床資料 | |
| 商品名 | Abegrin |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 892553-42-3  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6392H9908N1732O1996S42 |
| 摩爾質量 | 144,302.22 g·mol−1 |
埃達珠單抗（INN：Etaracizumab；開發代號：MEDI-522），或譯伊瑞西珠單抗，商品名Abegrin，是一種人源化單株抗體，正在研究用於治療轉移性黑色素瘤、前列腺癌、[1]卵巢癌[2]和各種其他類型的癌症。[3]它是由MedImmune生產的。[1]
它是Vitaxin（也稱為MEDI-523）的增強版。兩者均源自小鼠抗體LM609。[4]
參考資料
[編輯]- ^ 1.0 1.1 Etaracizumab (PDF). Statement On A Nonproprietary Name Adopted By The Usan Council. [2023-12-27]. （原始內容存檔 (PDF)於2012-03-19）.
- ^ Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, et al. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia. November 2008, 10 (11): 1259–67. PMC 2570602
. PMID 18953435. doi:10.1593/neo.08740.
- ^ Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Investigational New Drugs. February 2008, 26 (1): 35–43. PMID 17876527. S2CID 37221398. doi:10.1007/s10637-007-9077-0.
- ^ McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clinical Cancer Research. November 2005, 11 (21): 7851–60. PMID 16278408. doi:10.1158/1078-0432.CCR-05-0262.
